Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
about
Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesIntratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasisNext-generation sequencing: advances and applications in cancer diagnosisThe insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialThe myeloma stem cell concept, revisited: from phenomenology to operational termsTPL2 kinase regulates the inflammatory milieu of the myeloma nicheThe miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myelomaImplications of heterogeneity in multiple myeloma.Serial exome analysis of disease progression in premalignant gammopathies.Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.Curing myeloma at last: defining criteria and providing the evidence.Differential and limited expression of mutant alleles in multiple myeloma.Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.How I treat smoldering multiple myeloma.Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis.Dilemmas in treating smoldering multiple myeloma.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsLong-term disease control by pomalidomide-/dexamethasone-based therapy in a patient with advanced multiple myeloma: a case report and review of the literature.Pathogenesis beyond the cancer clone(s) in multiple myeloma.Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple MyelomaRNA-Seq following PCR-based sorting reveals rare cell transcriptional signaturesLongitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).Preclinical animal models of multiple myelomaGenome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.Leveraging premalignant biology for immune-based cancer prevention.Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease responseEZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.Incorporating novel agents in the management of elderly myeloma patients.Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit.The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.Identification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression.Current and potential epigenetic targets in multiple myeloma.The Tao of myeloma.Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma.
P2860
Q26799104-B33A5361-1BFD-458F-B810-16522B2690E6Q26991480-D8D009BD-7C2E-44AA-BA11-0D7822009710Q28073891-D5282EDE-5F1E-43EF-AF81-19A75E0E092FQ28075927-1DC96259-C310-469C-80E4-8F1C904FBFADQ28076070-854F66AC-F2D3-492B-90D8-482EBD36624DQ33714724-49F12AD1-8049-43F5-8CEC-A482937EDAA4Q33838260-0ECAC243-7A3F-4FD9-A446-C3965C84B210Q33914824-47681BE0-0AD0-4C2E-8F18-2A5D45F85E4AQ34079934-F0E90138-463C-4835-ABFC-145737636DA2Q34479418-FE1134BB-708C-4AB9-9374-CAD528292D59Q34508313-6863810C-A596-4D72-8D8C-9EE1CFA61460Q34508343-DFE8CBEC-2F71-421B-83CA-4B96699ED20EQ34525834-76FCE3AC-0431-4607-AE37-3BF31031C9C9Q34556156-5F6E6E00-55E2-4F43-B1E2-7413CE48B4BEQ34557651-F2C7E58F-EAD8-48F9-9621-0AFF2FEA59EEQ34580094-4C5D35DB-4DF1-4488-890D-0934FE62EDE5Q34607063-81FE8E4E-CFA2-47AF-92FF-0BE8174BE56BQ34716500-785562A1-3A96-4CD7-9463-FC3CEBED14F7Q35081172-1BD57354-1229-4A30-8CFC-C6B261BB250DQ35592482-EB6FDC14-2CF2-4BAD-BFBF-6B0FE7381D8CQ35607266-8A61C59D-E7CD-4F0D-8E37-61828387D1BCQ35925252-C7E31608-FAC5-4B90-A47E-D8363E93E51FQ36020424-135DAEC1-ED76-440B-A91A-6E7A7A00C549Q36306807-3699DE89-CA62-4FF5-B24A-18B9D7DB6B85Q36561366-91AA39A8-AB8E-42C3-8BD5-ECDFE0012947Q36916348-626DD048-7F99-458F-B8D1-959F7A18659BQ37304964-C7C92779-2D99-4C03-942E-E98EE9A72E35Q37402009-A67C59D7-FE0E-4503-B1F0-7D02E6917552Q37528285-3045772E-1BEF-4259-BF35-447357F51239Q37593761-C45E29E5-253A-48CD-8C40-2258284FC3EDQ37705811-E42AE604-ED33-4E4B-9415-E4A303066812Q38146974-EF2621F2-C297-4CDC-8449-221786E8CAE8Q38151195-832677E4-32C5-44C0-A3E7-0F677419A5DBQ38175395-44AEBD4F-EEBC-45C3-A7A9-050839901A05Q38192044-F75D90FD-8317-4D94-B498-49B3F0E6D110Q38199534-335F5F16-0537-468A-BF92-9E4740E18A77Q38210475-53A8B4CF-8E12-4FE6-B460-2FF22FC8346AQ38237360-7269ED4F-847D-4244-90D4-900186815713Q38255333-8B0891AA-7947-4301-A3D9-C10A1C4FB7B5Q38364172-458DD793-3963-4A19-99B3-EC19E0581E0D
P2860
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intraclonal heterogeneity is a ...... elopment of clinical symptoms.
@en
Intraclonal heterogeneity is a ...... elopment of clinical symptoms.
@nl
type
label
Intraclonal heterogeneity is a ...... elopment of clinical symptoms.
@en
Intraclonal heterogeneity is a ...... elopment of clinical symptoms.
@nl
prefLabel
Intraclonal heterogeneity is a ...... elopment of clinical symptoms.
@en
Intraclonal heterogeneity is a ...... elopment of clinical symptoms.
@nl
P2093
P2860
P50
P356
P1433
P1476
Intraclonal heterogeneity is a ...... elopment of clinical symptoms.
@en
P2093
David Bentley
David C Johnson
David Gonzalez
Faith E Davies
Lisa Murray
Lorenzo Melchor
Lucia Lopez-Corral
Martin F Kaiser
Sean Humphray
P2860
P2888
P304
P356
10.1038/LEU.2013.199
P50
P577
2013-07-02T00:00:00Z